US FDA declines to approve Intercept's fatty liver disease drug

Intercept Pharmaceuticals

22/06/2023 22:47

June 22 (Reuters) - The U.S. Food and Drug
Administration on Thursday declined to grant accelerated
approval for Intercept Pharmaceuticals'  ICPT.O  drug to treat a
type of fatty liver disease. 
    

 (Reporting by Sriparna Roy, Leroy Leo and Raghav Mahobe in
Bengaluru; Editing by Devika Syamnath and Shinjini Ganguli)
 ((Sriparna.Roy@thomsonreuters.com;))